carrier weathermaker 9200 manual
LINK 1 ENTER SITE >>> Download PDF
LINK 2 ENTER SITE >>> Download PDF
File Name:carrier weathermaker 9200 manual.pdf
Size: 3964 KB
Type: PDF, ePub, eBook
Category: Book
Uploaded: 16 May 2019, 14:35 PM
Rating: 4.6/5 from 594 votes.
Status: AVAILABLE
Last checked: 8 Minutes ago!
In order to read or download carrier weathermaker 9200 manual ebook, you need to create a FREE account.
eBook includes PDF, ePub and Kindle version
✔ Register a free 1 month Trial Account.
✔ Download as many books as you like (Personal use)
✔ Cancel the membership at any time if not satisfied.
✔ Join Over 80000 Happy Readers
carrier weathermaker 9200 manualThe 13-digit and 10-digit formats both work. Please try again.Please try again.Please try again. Used: GoodPlease choose a different delivery location or purchase from another seller.Strategies for managing symptoms and providing effective support to children and families are thoroughly detailed, with an emphasis on integrating medication and psychosocial therapies. Several chapters also address clinical work with adults with TS. User friendly and practical, the book includes three reproducible assessment tools. Then you can start reading Kindle books on your smartphone, tablet, or computer - no Kindle device required. Blending clinical wisdom with the best available evidence, the book will be a consultant on your desktop: an invaluable reference and an incomparable guide to getting patients in difficult situations unstuck. These are areas that are too often neglected when treating individuals with Tourette syndrome (TS), and that have been inadequately covered in other publications. It integrates the range of approaches which are needed in the treatment of what often is a complicated neurodevelopmental condition. It draws on the research which has informed the comprehensive, integrated, model of Tourette Syndrome.It is easy to read, enjoyable, informative, and overall clinically relevant. It is designed.to be consulted as a whole; however, each chapter can still be read separately to inform specific aspects of management of Tourette Syndrome, tic disorders, and associated conditions.Dr. Woods is a member of the Tourette Syndrome Association Medical Advisory Board and Behavioral Sciences Consortium and the Scientific Advisory Board of the Trichotillomania Learning Center. He has received funding from the National Institutes of Health to investigate the efficacy of behavior therapy for children and adults with Tourette syndrome. John C.http://www.roletyhanarol.pl/files/environmental-protection-agency-wastewater-treatment-manuals.xml
- Tags:
- carrier weathermaker 9200 manual, carrier weathermaker 9200 manual reset, carrier furnace 9200 manual, carrier weathermaker 9200 installation manual, carrier weathermaker 9200 parts manual, carrier weathermaker 9200 service manual, carrier weathermaker 9200 manual, carrier weathermaker 9200 manual, carrier weathermaker 9200 manual pdf, carrier weathermaker 9200 manual, carrier weathermaker 9200 manual pdf.
Piacentini, PhD, is Professor of Psychiatry and Biobehavioral Sciences in the David Geffen School of Medicine at the University of California at Los Angeles. He is the Chair of the Tourette Syndrome Association Behavioral Sciences Consortium and a Founding Fellow of the Academy of Cognitive and Behavioral Therapies. Dr. Piacentini is the recipient of National Institutes of Health grant awards pertaining to the etiology, assessment, and treatment of Tourette syndrome, obsessive-compulsive disorder, and other child anxiety disorders. John T. Walkup, MD, is Associate Professor of Psychiatry and Behavioral Sciences at the Johns Hopkins Medical Institutions. Dr. Walkup is the current Chair of the Medical Advisory Board of the Tourette Syndrome Association. He is the Principal Investigator of the Johns Hopkins’ Research Unit of Pediatric Psychopharmacology and Psychosocial Interventions and has been the Principal Investigator on a number of clinical trials evaluating interventions for childhood psychiatric disorders, including Tourette syndrome. Full content visible, double tap to read brief content. Videos Help others learn more about this product by uploading a video. Upload video To calculate the overall star rating and percentage breakdown by star, we don’t use a simple average. Instead, our system considers things like how recent a review is and if the reviewer bought the item on Amazon. It also analyzes reviews to verify trustworthiness. Please try again later. James Claiborn 5.0 out of 5 stars Would buy from this buyer again.My son has compulsive disorder with tics and the suggestions were very helpful. The book is written with clarity and very helpful information.Eventually, if I practice what it says, it may make a big positive change in my life. Learn More. Each chapter of the book offers something unique, and though all of them could be pulled out and used separately, the authors recommend an integrated treatment approach afforded by the use of the whole book.http://www.gwardiajuvenia.pl/zdjecia/fck/environmental-safety-and-health-manual.xml In the Forward, Dr. Peter Hollenbeck describes the progress since the description of TS by Gilles de la Tourette. He highlights the relatively recent development of Habit Reversal Therapy (HRT). HRT arose after decades of studies of the basal ganglia, which showed that the basal ganglia encode motor sequences, and that they can change and modify their circuitry in response to appropriate types of conditioning. In HRT, the therapist elicits in fine detail from the patient the premonitory urges, the circumstances around which the tics arise, and the cues warning the patient that the tics are coming. The patient is then instructed to develop and practice a competing response, usually an action opposite to, or incompatible with, the tic. This usually significantly reduces tic severity and functional impairment. In chapter one, the editors report on the evolution in thinking about Tourette Syndrome, starting with Gilles de la Tourette’s neurological and genetic view, to a psychodynamic view, and, as of the late 1960’s, a medical view. As of 1999, the emphasis has been on an integrated biological, psychological and social approach. Based on this integrated conceptual model of TS, the Tourette Syndrome Association formed the Behavioural Sciences Consortium (BSC) in 2002. Chapter two, Characteristics of Tourette Syndrome, mentions that Gilles de la Tourette’s description of TS was accurate. We now see the disorder as a relatively common neurobehavioural disorder. A clinical description of tics is given, followed by the differential diagnosis of tic disorders, as well as the diagnostic criteria for the disorders. A brief summary of the course and prognosis, epidemiology, phenomenology and comorbidity follow. The chapter ends with a brief explanation of current explanatory models, from a neurological and environmental perspective. Chapter three covers the differential diagnosis of tics and other movement disorders; assessment of tic severity; premonitory sensations; and assessment of current functioning. Movement disorders which may resemble tics include myoclonus, dystonia, Sydenham or Huntington Chorea and restless leg syndrome. Practitioners not familiar with these disorders are advised to obtain a neurological consultation. A medical evaluation may help elucidate the cause of eye blinking, sniffing and throat clearing. Stereotypic movement disorders are usually single, do not wax and wane, and do not vary in anatomical location. If there is no presence nor history of simple tics of the head, and if the patient has a development disorder, then the disorder is more of a stereotypic nature. Tic severity includes factors such frequency, discomfort, pain, complexity, intensity and noticability. The Yale Global Tic Severity Scale ( Leckman et al. 1989 ) is useful in assessing severity. The latter can be deceiving because tics may be suppressed during interviews. Premonitory sensations can be assessed with the Premonitory Urges for Tics Scale (included in Appendix 3.3). Chapter four describes the assessment of co-occurring psychiatric disorders, e.g. Attention Deficit Hyperactivity Disorder (ADHD), Obsessive-Compulsive Disorder (OCD), anxiety disorders and pervasive developmental disorders. Chapter five elaborates on the genetic and neurobiological bases for TS. Genetic studies remain inconclusive; this could be caused by failure to include epigenetic factors. Neurological studies support the concept of an abnormality in the corticostriatal circuitry. Chapter six focuses on neurocognitive deficits in TS. There appears to be a consensus that Verbal IQ is significantly greater than the Performance IQ in many patients with TS, suggestive of problems in visuospatial, perceptual, and motor abilities. Studies also suggest difficulties with executive functions; for example, poorer divided attention abilities, problem-solving abilities, and response inhibition. There may be problems with procedural memory. The most consistent finding is visuomotor integration impairment. Fine motor skill dependent on visuoperceptual processes are consistently impaired in patients with TS, regardless of the presence of ADHD. Mild neurocognitive abnormalities are associated with TS from childhood to adulthood. Girls are slower than boys in Letter Word Fluency. Mounting evidence suggests that comorbidities such as ADHD and OCD exacerbate the cognitive impairments found in TS. Deficits in visuomotor integration and response inhibition may be specific to TS. These deficits impact on symptom presentation, such as aggressiveness, impulsiveness, mood disturbances and poor social skills, and on the treatment response. Treatment may be targeted toward the specific deficits. Part II of the book covers the medical management of TS. Chapter 7 discusses the medical management, which consists of treatment of the most impairing conditions. Tics are very apparent and can distract from important comorbidities, especially internalizing ones. Tics were traditionally treated with typical neuroleptics, like haloperidol, pimozide or fluphenazine, though these medications are gradually being replaced by the atypical neuroleptics, like risperidone, olanzapine, ziprasidone, quetiapine, and aripiprazole, The use of other dopamine-modulating agents (pergolide, sulpiride, tiapride, tetrabenazine, levodopa, talipexole, rapinirole, metoclopromide), as well as alpha-adrenergic agents (clonidine and guanfacine) are discussed. Other tic suppression agents (baclofen, nicotine, mecamylamine and delta-9-tetrahydrocannibinol) are seen as not promising. The uses of penicillin and intravenous immunoglobulin in infection and in autoimmune-based treatments have not been proven effective. The authors then discuss the treatment of associated comorbid disorders —ADHD and OCD — and end with the discussion of treatment refractory cases and of complex cases. Chapter eight discusses the psychosocial treatment of tics and of intentional repetitive behaviors associated with TS: contingency management, function-based interventions (examines under which circumstances the tics arise), massed practice (consists in voluntarily rapidly producing the tics), relaxation training, hypnosis, self-monitoring, exposure with response prevention, and habit reversal. Particular attention was given to the latter. Medications rarely eliminate tics, and they have side effects which result in poor compliance; therefore the treatments discussed in this chapter can be useful. Chapter nine discusses the management of comorbid internalizing disorders in TS; for example, OCD, anxiety disorder, depressive disorder, and the use of cognitive behavioral therapy for these disorders. Chapter ten discusses the assessment, phenomenology and treatment (psychosocial and medical) of disruptive behaviour in patients with TS. Anger and non-compliance are a large part of this problem. The chapter reported on a large number of studies dealing with the issues. It is unclear whether tic severity contributes to difficult behaviour. The presence of ADHD worsens it. Part three, Clinical Management of Secondary Problems, chapters eleven, twelve and thirteen deal with family issues, school issues, and social and occupational difficulties of persons with TS, and discusses when and how to intervene. I enjoyed reading this book. It is thorough, and it gave a very good up to date review and critique of the literature on every aspect of TS. It is written in an authoritative manner, giving up to date methods for assessment and treatment of every aspect of this disorder and of its complications. I highly recommend it for all practitioners who deal with patients who suffer from TS. References Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, et al. The Yale Global Tic Severity Scale: Initial testing of a clinician-rated scale of tic severity. Currently available treatments to reduce tic s are limited by variable clinical response and frequent adv erse effects. They in clude alpha-2 agoni sts, antipsychotic s (first and second generation), tetrabenazine, benzodiazepines, and habit reversal therapy. Some new and emerging (but unproven) treatments are also discussed, including topiramate and dopamine ag onists. In addi tion, there is incr easing inte rest in deep brain st imulation, but this is not ye t ready for gene ral use. Introduction In the 1800s, the French neurologist Georges Gilles de la Tourette descri bed the first nine cases of To urette ’ s syndrome, characterized by childhood onset of multi- ple motor and vocal tics. In our current nomenclatur e in the DSM-IV, the name h as changed to Tourette ’ s disorder (TD), which includes specific diagnostic cri te- ria: the presence of multiple motor tics and at least one vocal tic for greater than 1 year; onset prior to age 18 years; and frequent tics, often occurring in bouts, which cause marked distress or impairment and are not secondary to another condition. The most recent iteration of the DSM-IV-TR has eliminated the impair- ment criterion. Clinical manifestations of tics can be very diverse and can be classified as either simple or complex movements and vocalizations. Simple motor tics are characterized by quick jerks of typically single muscle groups. More complex, purposeful, or coordinated movements are termed complex motor tics. Some motor tics have a slow, twisting, or sustained quality that may resemble dystonia, and thus they are described as dystonic tics. Simple vocal tics a r ei n a r t i c u l a t en o i s e s or sounds, whereas complex vocal tics are syllables, words, or phrases that have linguistic meaning. Virtu- ally any movement or sound can be the manifestation of a tic if it is involuntary. Despite the notoriety of the complex vocal tic coprolalia (involuntary uttering of obscenities), only a small minority of patients experi- ence this symptom. Tics have a number of other char- acteristic features that are fairly specific. They are suppressible, tend to wax and wane, and also tend to change location over time. Patients often will describe an inner tension or urge that is transiently relieved by the tic itself. Most expert clinicians now view TD, CMTD, CVTD, and transi ent tic diso rder as vari ants of the sa me primar y dis- order. The se are viewe d as prima ry tic diso rders bec ause they are thought to derive from mostly hereditary factors (although en vironment may c ontribute) an d do not re- flect bra in dysfun ction sec ondary to o ther caus es, inclu d- ing drug s (most not ably ne urolept ics). Tics may be associated with a variety of other con- ditions. Consid ered to be secondary t ic disorders,t h e s e include common neurodevelopmental disorders (eg, autism), pervasive developmental disorder (PDD), Asperger ’ s syndrome, mental retarda tion, and develop- mental stutte ring. TD, ADHD, and OCD occur comorbidly so often in cl inical samples that they are collectively re ferred to as the “ clinical tri ad ” of the TD neuropsychiatric spectrum and may be challenging to treat. Although tics are very common in the school-age population and are most often mild, tics may be more severe and contribute to disability in a variety of ways. They can be embar rassing to indiv idual patien ts, leading to social isolati on, low self-est eem, anxiety, and depres- sion. Some tics a re painful. Tics ma y interfer e with critical school and work activities such as reading and writing and may make public speaking difficult. The mental energy expended to suppre ss tics in school or in other public setting s may interfere wi th attention and co ncen- tration that should be more productively directed else- where. Obscene or insulting tics may lead to fights. Frequent tic s may interfere with a ctivities of da ily living such as eating or dressi ng. In both primary an d second- ary disorders, tics are appropriate targets of therapy because they of ten contribu te to functional di sability. Assessment of the educational, family, and social resources and of the patient ’ s strengths, competencies, and coping skills is essential. As antihypertensive agents, these are not labeled for tic treatment, but in clinical trials they have reduced tics by about 30 to 35. Although these medications are Tourette ’ s Disorder Lyon et al. 275 The most feared side effects of these agents, tardive dyskinesia and neuroleptic malignant syndrome, a re rarely seen in the treatment of TD. Such therapy can be used in conjunction with or independent of medications. Other stimula nts with known efficacy for ADHD can also be considered, but they may need to be withdrawn if tic exacerbations occur and are sustained. Effective treatments may include serotonin reupta ke inhibitors, cogni- tive behavioral therapy, or both. Unfortunat ely, no published tria ls have yet confirm ed the efficacy of an y such treatments. Pharmacologic treatment Alpha-2 adrenergic agonists Drugs in this class have demonstrated efficacy for both tics and ADHD in randomized clinical trials, so this class is a good first-line choice for patients with both conditions. Clonidine binds to the three subtypes of alpha-2 receptors (A, B, and C), whereas guanfacine binds more selectively to alpha-2 A receptors, which appear to enhance prefrontal function. Guanfa- cine is used in clinical practice with similar efficacy, a more favorable side effect profile, and more convenient (daily or twice-daily) dosing.The maximum dose is typically 0.4 mg daily in divided doses. Starting doses for clonidine and guanfacine in children can be half of adult doses. Contraindications Known hypersensitivity to the product. These medications can increase the risk of low blood pressure and slow heart rate. Main side effects Both clonidine and guanfacine are associated with sedation, fatigue, and somnolence. Reductions in heart rate and blood pressure are modest and rarely lead to discontinuation of treatment. Special points Abrupt withdrawal can cause rebound hypertension (including posterior re- versible encephalopathy syndrome), headache, and tic exacerbations. Tourette ’ s Disorder Lyon et al. 277 Contraindications Known hypersensitivity. Main drug interactions Fluoxetine and paroxetine have been shown to increase the plasma concen- tration of risperidone. Main side effects As with all antipsychotics, there is variable risk of extrapyramidal symptoms including parkinsonism and akathisia, tardive dyskinesia, weight gain, or sedation. Special points None of the atypical antipsychotics have been approved by the US Food and Drug Administration (FDA) for TD, so all use is off-label. Cost All atypical antipsychotics are generally more expensive than the classical neuroleptics, owing to their more recent introduction to the market. Classic neuroleptics This class of dopamine blocking agents has long been used in the treatment of TD. Haloperidol and pimozide remain the only two medications with FDA approval for the treatment of TD. Standard dosage The patient ’ s age, tic severity, previous response to other medications, and concomitant medications or disease state should be considered when decid- ing upon initial dosage and titration. An initial starting dose of 0.5 mg for haloperidol is typical for children and adolescents, the maximum dose (rarely attained because of side effects) is 20 mg per day. Contraindications Haloperidol is contraindicated in severe toxic central nervous system depres- sion or comatose states from any cause and in individuals who are hypersen- sitive to this drug or who have Parkinson ’ s disease. There are several contraindications with the use of pimozide, so referring to the drug label is strongly recommended before initiating this medication. Most important are congenital long QT syndrome, a history of cardiac arrhythmias, the use of other drugs that prolong the QT interval, severe toxic central nervous system de- pression, or comatose states from any cause. Main drug interactions Because pimo zide can pr olong the QT c interval on the ECG, an additive e ffect would be antic ipated if admi nistered wit h other drugs (e g, phenoth iazines, tri - cyclic antid epressant s or antiarrh ythmic agen ts) that also ca n prolong the QTc interval. Accordingly, pimo zide should n ot be given w ith dofetil ide, sotal ol, quinidine, o ther Class Ia and II I antiarrhy thmics, me soridazin e, thioridaz ine, chlorpro mazine, drope ridol, spa rfloxaci n, gatifloxa cin, moxiflo xacin, hal ofan- trine, meflo quine, pent amidine, ars enic trioxi de, levomet hadyl acetat e, dolasetr on mesylate, pr obucol, tac rolimus, zip rasidone, or other drugs th at have demon- strated QT c prolongat ion as one of th eir pharma codynami c effects. Al so, the use of 278 Movement Disorders Main side effects As with all neuroleptics, there is variable risk of extrapyramidal symptoms including parkinsonism and akathisia, tardive dyskinesia, weight gain, or sedation. Special points An ECG should be done at baseline for pimozide, and periodically thereafter, especially during the period of dose adjustment. In clinical studies, tetrabenazine has been found to be effective in a wide range of hyperkinetic movement disorders, including three large TD clinic populations (class IV). One group reported their experience with add-on therapy for 33 pediatric patients (mean age, 11 years) with hyperkinetic movement disorder, in- cluding 10 with TD. Dosages in TD patients range d from 37.5 mg to 200 mg per day, divided three times daily. Long-term efficacy was suggested by the experience of another group. An Italian collaboration also reported long-term experience with 120 TD patients (mean age, 21), primarily as add-on therapy. Recently, clinical trials investigating tetrabenazine for the treatment of chorea associated with Huntington ’ s disease found the drug to be safe and efficacious, leading to approval by the FDA for this indication. Its use for TD is considered off-label. Standard dosage It is generally recommended to begin with one 12.5-mg tablet at night and to titrate upwards in 12.5-mg increments to three times per day. The FDA recommends cytochrome CYP2D6 genetic testing (for slow metabolizer status) before reaching 75 mg per day, but in the reported clinical practice series, careful titration alone was used without any serious or life- threatening events. Contraindications Tetrabenazine is contraindicated in patients who are actively suicidal and in patients with untreated or inadequately treated depression. Tetrabenazine is also contraindicated in patients who have impaired hepatic function or who are taking monoamine oxidase inhibitors or reserpine. At least 20 days should elapse after stopping reserpine before starting tetrabenazine. Tourette ’ s Disorder Lyon et al. 279 The effect of moderate or weak CYP2D6 inhibitors such as duloxetine, terbinafine, amiodarone, or sertraline has not been evaluated. Main side effects Depression is a common side effect. Neuroleptic malignant syndrome (NMS), akathisia, agitation, parkinsonism, dysphagia, and arrhythmias involving QT prolongation have been reported with use of tetrabenazine. Adverse reactions associated with tetrabenazine, such as QTc prolongation, NMS, and extrapyramidal disorders, may be exaggerated by the concomitant use of dopamine antagonists. Cost Tetrabenazine can be quite expensive, and an assistance program is available for eligible patients. No large-scale trials have been conducted to date. Nonetheless, selective use of benzodiazepines during acute or severe tic exacerbations is often quite helpful. Response to indi- vidual drugs may vary. Standard dosage In the absence of solid evidence, it is reasonable to begin with clonazepam. Contraindications Clonazepam should not be used in patients with a history of sensitivity to benzodiazepines, nor in patients with significant liver disease. It is contrain- dicated in acute narrow-angle glaucoma. Main drug interactions Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine, or phenobarbital. The effect of clonazepam on the metabolism of other drugs has not been investigated. Main side effects Sedation and imbalance may occur but usually improve over time. Dysphoria or disinhibition also may occur. Interventional procedures Botulinum toxin Evidence for the use of botulinum toxin types A and B injections (including one class II trial for simple motor tics and one class IV study for phonic 280 Movement Disorders Per-muscle titration guidelines for treatment of cervical dystonia and blepharospasm are provided in the package insert. Contraindications Presence of infection at proposed injection sites, hypersensitivity to any bot- ulinum toxin preparation or to any of the components in the formulation, or any motor neuron, myopathic, or neuromuscular junction disorder. Complications Local muscle atrophy can occur with chronic use. Dry mouth or dysphagia can occur with injections in cervical or facial muscles. Patients should also be advised of the (very rare) risk of diffuse muscle weakness, even with focal injections. Special points Local intramuscular injections of botulinum toxin can be useful, but this ap- proach is limited because of expense, short duration of benefit, and use re- stricted to only one or two disabling types of tics (eg, eye blinking, neck jerks). Surgery Deep brain stimulation Limitations of pharmacologic treatments have led to the recent use of surgical deep brain stimulation (DBS) to treat disabling tics in patients with TD. However, the exact location of leads is not standardized across centers, and influence on comorbidities and other psychosocial factors underlying tic exacerbations must also be carefully considered. Standard procedure DBS for TD should be performed only as part of a clinical trial or as part of an International Registry. (Contact Kevin McNaught, Scientific Adviser for the Tourette Syndrome Association, www.tsa-usa.org, for details.) Contraindications Medical conditions preventing general anesthesia and neurosurgery. Complications Perioperative complications related to surgery and anesthesia (mortality rates G 1 in recent publications). The results of a large class I randomized trial of Tourette ’ s Disorder Lyon et al. 281 Contraindications None. Complications Not sufficiently tested with severe, treatment-refractory cases. Special points Results from the CBIT trial are eagerly awaited. To date, HRT has not been directly compared with medications in any trial. Active focusing on premoni- tory sensations and active mental attempts to carry out tic-competing actions could detract from more appropriately directing attention elsewhere (eg, in a school classroom). Cost Weekly therapy sessions may yield costs higher than for medication. This is based on glutamate ’ s major role in cortico-striatal-thalamo-cortical circuit s (CSTC), the recognized extensive interaction between glutamate and dopamine systems, results of familial genetic studies, and data from neuro- chemical analyses of postmortem brain samples. However, data from published open-label trials have conflicted; a class I trial is under way. In this trial, 26 of participants receiving topiramate and 29 of those receiving 282 Movement Disorders Topiramate is FDA-approved for pro- phylactic management of migraine, and may be considered in TD patients for this indication. Both studies were conducted at a single academic center and await duplication. The mean effective dose in a class I study was 100 mg daily. Contraindications Topiramate should not be administered to individuals with history of glau- coma, nephrolithiasis, or known hypersensitivity. Main side effects The main side effects include sedation, cognitive slowing, weight loss, and dysgeusia. Complications Rare but potentially serious complications of acute angle closure glaucoma and nephrolithiasis have been reported. Special points Use caution in renal or hepatic impairment. Avoid abrupt withdrawal. Dopamine agonists There was some interest in the use of dopamine agonists, namely pergo- lide, for the treatment of TD, perhaps because of its paradoxic reduction of tics in low dosages. This effect may be analogous to the beneficial effects in restless legs syndrome (RLS). However, pergolide was removed voluntarily from the US market by its manufacturer in March 2007 after findings emerged for significantly increased rates of cardiac valvular dysfunction in patients with Parkinson ’ s di sease who took pergolide and another dopamine agonist, cabergoline. The findings were consistent with abundant clinical and mechanistic evi- dence that pergolide and cabergoline function as dopamine agonists and also activate the serotonin receptor 5-hydroxytryptamine 2B (5-HT2 B), causing a histologically distinct form of fibrotic valv ulopathy. Cabergoline is approved in the United States for the treatment of hyperprolactinemic disorders at doses much lower and safer than those used in Parkinson ’ s disease; there are no published reports concerning its use in TD.